EUVIMEDOtkrijte EUVIMED
CrossrefInformacijska kartica

Anastomosis versus rectal stump procedure in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal peritoneal metastases: A comparative study

Lana Ghanipour, Lana Othman Mahmmud, Peter Cashin, Gabriella Jansson Palmer, Mirna Abraham‐Nordling

Colorectal Disease · 2025-10 · 27 (10)

DOI: 10.1111/codi.70256 ↗
SažetakBibliografski podaci

Sažetak

Abstract Aim Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard treatment for peritoneal metastases (PM) of colorectal or appendiceal origin. Rectal anastomotic leakage (RAL) or rectal stump blow‐out is a serious complication following rectal resection after CRS‐HIPEC. This study aimed to compare outcomes between ileo‐/colorectal anastomosis and rectal stump procedure and to identify risk factors for RAL and blow‐out. Method Data were retrospectively collected between 2012 and 2024 from a prospectively maintained HIPEC Registry and supplemented with the review of medical records. Postoperative complications and the prevalence of RAL or blow‐out were registered. Pearson's chi‐squared test was used to compare differences in categorical variables. Logistic regression was used to identify risk factors for RAL and blow‐out. Results Among 1271 CRS‐HIPEC procedures, 332 involved rectal resections. Patients received either an ileo‐/colorectal anastomosis ( n = 158) or had a rectal stump procedure ( n = 174). RAL occurred in 5.7% and blow‐out in 2.9% ( p = 0.201). In the rectal stump group, patients were older (65 vs. 59 years; p = 21 (OR 6.47; 95% CI: 0.84–50.1). Conclusion Both reconstruction strategies following rectal resection in CRS‐HIPEC were associated with low rates of RAL or blow‐out. No independent risk factors were identified, indicating that the choice of surgical approach should be individualized based on clinical context rather than presumed leakage risk.

Znanje koje odgovara vašem radu.

Od besplatnog početka i osobnog pretraživanja literature do potpunog paketa Research Suite.

Prikaži tarife →

Jesu li uključeni svi cjeloviti tekstovi izdavača?

Ne. Bibliografski zapisi, sažeci i cjeloviti tekstovi različiti su sadržaji. Hoće li cjeloviti tekst biti dostupan ovisi o izvoru, Open Accessu i vašim postojećim licencama. Tarifa EUVIMED ne zamjenjuje dodatna izdavačka prava.

Prikaži tarife →